Kidney Res Clin Pract.  2022 Sep;41(Suppl 2):S63-S73. 10.23876/j.krcp.21.288.

Diabetic kidney disease treatment: new perspectives

  • 1Division of Nephrology and Hypertension, The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, USA


Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide, as the obesity epidemic and the burden of diabetes continue to rise globally. In general, guideline management of patients with DKD recommends lifestyle modifications, blood pressure and glycemic control, and dyslipidemia treatment along with other cardiovascular disease risk reduction measures. The inhibition of the renin-angiotensin system (RAS) using an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker remains the foundational therapy for DKD. In type 2 diabetes (T2D), significant advances in therapeutics, including the sodium-glucose cotransporter-2 inhibitors (SGLT2i), the glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor agonist (MRA) finerenone, have dramatically expanded the armamentarium for treating DKD and its cardiovascular complications. Initiating, optimizing, and sustaining evidence-based pharmacological therapy using a therapeutic combination of RAS inhibitor + SGLT2i/GLP-1 RA + nonsteroidal MRA + statin is likely to significantly improve outcomes for T2D with DKD. Research into potential novel therapeutic targets for DKD remains particularly active and brings much anticipation and optimism to this field.


Chronic kidney diseases; Diabetic kidney disease; End-stage kidney disease; Glucagon-like peptide-1 receptor; Mineralocorticoid receptor antagonists; Renin-angiotensin-system; Sodium-glucose transporter 2 inhibitors
Full Text Links
  • KRCP
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: